Report Details:
15 Companies Covered
220 Pages
Market Highlights
Global Gene Panel Market size was valued at USD 3.56 Billion in 2025, and the market is projected to grow from USD 4.12 Billion in 2026 to USD 14.03 Billion by 2035, registering a CAGR of 14.58% during the forecast period 2026–2035.
Gene panel is a test that analyzes multiple genes for cancer-associated mutations at the same time. Gene panels offer a middle ground between single-gene sequencing (like BRCA1), which is certainly involved in disease risk and sequencing every gene in the genome. Gene panels enable the simultaneous screening of several genes. Panels are typically customized for specific screening purposes; thus, the genes and specific gene regions on such panels are unique to the screening goals. The increasing prevalence of cancer and the benefits of gene panels are expected to drive the growth of the global gene panel market. However, limitations in gene panel testing and inaccuracy of the test are expected to hamper the growth of the market.
Segment Analysis
The Global Gene Panel Market has been segmented by product & service, Technique, Design, Application, and End User.
The market, based on product & service, has been bifurcated into test kits and testing services. Based on the technique, the global gene panel market has been bifurcated into the amplicon-based approach and hybridization-based approach. On the basis of design, the global gene panel market has been bifurcated into predesigned gene panels and customized gene panels. Based on the application, the global gene panel market has been classified as cancer risk assessment, diagnosis of congenital disorders and pharmacogenetics. The global gene panel market based on end-user has been divided into hospitals, diagnostic laboratories, and others.
Gene Panel Regional Analysis
The global gene panel market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are likely to hold the largest share of the global gene panel market during the assessment period. The rising prevalence of cancer and the presence of well-established players are expected to support the dominance of the Americas during the forecast period. Europe established substantial growth in the market owing to the incidence rates for all cancers projected to rise by 2% in the UK between 2014 and 2035, to 742 cases per 100,000 people by 2035. This rising case of cancer, along with improving the efficiency of gene panels, is expected to drive the growth of the market. Asia-Pacific is estimated to be the fastest-growing regional market due to the growing healthcare expenditure and the presence of a large patient pool. The gene panel market in the Middle East & Africa is expected to witness gradual growth due to the increasing healthcare expenditure, rising investments by major market players, and growing patient pool in this region.
Key Players
MRFR recognizes the following companies as the Key Players in the Global Gene Panel Market— Agilent Technologies Inc. (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany), Illumina Inc. (US), BGI Genomics (China), Integrated DNA Technologies, Inc. (the US), GENEWIZ (US), Novogene Corporation (US), Personalis, Inc. (the US), GATC Biotech AG (Germany), ArcherDX, Inc. (the US), GeneDx (Switzerland), and CENTOGENE AG (Germany).
Key Findings of the Study
• By Product & Services
- Test Kits dominated the Gene Panel Market with a 60.05% revenue share in 2025, reflecting strong demand for ready-to-use targeted genomic sequencing kits across clinical laboratories.
- Testing Services are forecast to expand at a 15.23% CAGR through 2035, driven by outsourced oncology gene panel testing from smaller hospital systems.
• By Technique
- Amplicon-based workflows captured 65.46% of the Gene Panel Market share in 2025, favored for their cost efficiency in multi-gene cancer testing applications.
- Hybridization capture approaches are poised to grow at a 15.16% CAGR to 2035 as larger panels and hereditary disease gene panels demand higher uniformity of coverage.
• By Application
- Cancer Risk Assessment accounted for 52.45% of the Gene Panel Market in 2025, reflecting widespread NCCN guideline adoption for tumor profiling.
- Pharmacogenetics is projected to advance at a 15.11% CAGR through 2035, aided by growing preemptive prescribing programs.
• By End User
- Hospitals & Clinics held a 51.98% share of the Gene Panel Market in 2025, anchored by in-house molecular pathology departments.
- Diagnostic Laboratories are set to grow at a 14.99% CAGR to 2035 as reference labs scale high-throughput next-generation sequencing panels.
• By Region
- North America led the Gene Panel Market with 38.95% revenue in 2025, supported by favorable CMS reimbursement policies.
- Asia-Pacific is forecast to expand at a 15.25% CAGR to 2035, driven by national genomics initiatives and rising oncology gene panel testing demand.
